Clinical Investigation of NMS Assist

Launched by UNIVERSITY OF PLYMOUTH · Jun 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new digital tool called NMS Assist, designed to help people with Parkinson's disease (PwP) manage their non-motor symptoms (NMS) more effectively. These symptoms can include issues like pain, sleep problems, and mental health challenges, which can significantly impact daily life. The goal of the trial is to encourage PwP and their care partners to better understand and manage these symptoms, ultimately improving their quality of life. Over the course of 12 months, 60 participants will use the NMS Assist tool while their experiences and any improvements in their communication with healthcare professionals are monitored.

To be eligible for this study, participants must be at least 18 years old, fluent in English, and able to use a smartphone. They should not be living in a care facility and must normally receive care from the Parkinson's service involved in the trial. Participants can expect to learn more about their symptoms and gain confidence in managing them, while providing valuable feedback about their experience with the NMS Assist system. This trial aims to make managing Parkinson's non-motor symptoms easier and more effective, benefiting both patients and healthcare providers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to provide informed consent and comply with intervention requirements
• • 18 years or older
• • Be fluent in English
• • Not resident in a care or nursing home
• • Ambulant
• • Have compatible smartphone/data access
• • Normally under the care of the Parkinson's service in the participating organisation
• • Participant's HCP in the participating organisation consented to participate in the study
• Exclusion Criteria:
• • Secondary cause of parkinsonism
• • Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
• • Living in residential care facilities
• • Previous involvement in development or testing of the NMS Assist system
• • Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance (e.g. life expectancy \<6 months)
• • In a dependent/unequal relationship with anyone involved in the research or care teams